CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis
Authors
A Barlier
A Colao
+46 more
A Spada
A. Bargiota
A. Chrisoulidou
A. Theodoropoulou
AO Vortmeyer
C Park
CA Landis
D. A. Vassiliadi
E Ballare
EF Adams
EF Adams
G Faglia
G. Kanakis
H Madsen
HJ Kim
I Yang
J Yasufuku-Takano
JA Gilbert
JP Higgins
L Katznelson
L Katznelson
L. Papanastasiou
LV Hedges
M Buchfelder
M. Alevizaki
ML Jaffrain-Rea
MR Gadelha
N Karavitaki
OM Dekkers
P Anagnostis
P Chanson
P Chanson
PE Harris
PU Freda
PU Freda
R DerSimonian
S Larkin
S Melmed
S. K. Tigas
S. Tsagarakis
SL Fougner
SL Fougner
SO Akintoye
V Mendoza
Y Bakhtiar
Z. A. Efstathiadou
Publication date
1 January 2015
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Objective: Somatic mutations in the GNAS1 gene, which encodes the alpha-subunit of G stimulatory proteins (gsp), are frequently detected in somatotroph pituitary tumors and have been associated to specific clinical and histopathological characteristics. However, the question whether the presence of a somatic gsp mutation affects the response to somatostatin analog treatment remains unresolved. Design: Following a literature search, we performed a meta-analysis, including 8 eligible studies, in order to estimate the effect of gsp mutation on the percent reduction of growth hormone (GH) levels during an acute octreotide suppression test (OST). A total of 310 patients with acromegaly [126 gsp (+) and 184 gsp (−)] were included in the analysis. Results: The presence of the gsp mutation was related with a greater reduction in GH levels on OST [Weighted Mean Difference (WMD): 9.08 % (95 % CI, 2.73, 15.42); p = 0.005; random effects model]. There was significant heterogeneity for this effect estimate (I2 = 58 %, p value for heterogeneity = 0.02). A sensitivity analysis after exclusion of a study with different methodology of OST provided similar estimates [WMD: 6.93 % (95 % CI, 1.40, 12.46); p = 0.01], albeit with no significant heterogeneity (I2 = 35 %, p value for heterogeneity = 0.16). Conclusions: The present meta-analysis suggests a role for gsp mutation as a prognostic factor of treatment response to somatostatin analogs. © 2015 Springer Science+Business Media New Yor
Similar works
Full text
Available Versions
University of Thessaly Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ir.lib.uth.gr:11615/27283
Last time updated on 07/12/2017
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1007%2Fs11102-015-...
Last time updated on 03/12/2019